# Andera Partners

> Andera Partners is a VC fund in Paris backing Biotechnology and Health Care. See 185 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Paris, France
- Total investments: 185
- Last investment: Jul 2026
- Lead investor: 42%
- Fund size: $466M
- Last fund: Oct 2022
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/anderapartners/
- X (Twitter): https://twitter.com/ederothschild
- Website: https://www.anderapartners.com/en/
- Facebook: https://fr-fr.facebook.com/ederothschildgroup

Andera Partners is a VC fund in Paris focused on Biotechnology and Health Care. Andera Partners, formerly known as Edmond de Rothschild Investment Partners (EdRIP) As heir to the traditions and values that have ensured the success of the Rothschild family for 250 years, the Edmond de Rothschild Group has established itself over time as a leading player in European finance. Its activities are grouped around two major areas:Private Banking and Asset Management. The Group offers wealthy families, entrepreneurs, and large institutions a full range of solutions combining a culture of tailored solutions, stability, performance, and innovation. The Edmond de Rothschild Group’s offering is characterised by strong convictions, with the desire to guarantee to each of its customers: A unique, close relationship, underpinned by the know-how and the variety of expertise of a large international group; Autonomous, experienced teams, who anticipate economic trends and innovate to establish long-term performance; The recognised stability, strength, and independence of a family-owned financial group. Founded by Baron Edmond de Rothschild in 1953, the Group has been chaired by his son, Baron Benjamin de Rothschild, since 1997.

## Contacts

5 contacts available for Andera Partners. Shizune tracks 25 team members at Andera Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/edmond-de-rothschild-investment-partners?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $7M–$83M |
| Series B | $14M–$85M |
| Private Equity | $110M–$237M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 55 | 30% |
| Health Care | 49 | 26% |
| Medical | 31 | 17% |
| Therapeutics | 22 | 12% |
| Medical Device | 20 | 11% |

91 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 38 | 21% |
| Private Equity | 33 | 18% |
| Series A | 28 | 15% |
| Series C | 22 | 12% |
| Funding Round | 21 | 11% |

12 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 72 | 39% |
| United States | 20 | 11% |
| Germany | 9 | 5% |
| Belgium | 5 | 3% |
| Switzerland | 5 | 3% |

12 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| François Boudreault | Censor | 1 | https://shizune.co/investors/profile/franois-boudreault |
| Francois Xavier Mauron | Partner | 1 | https://shizune.co/investors/profile/francois-xavier-mauron |
| Gilles Nobecourt | Partner | 5 | https://shizune.co/investors/profile/gilles-nobecourt |
| Guillem Laporta | Analyst | 3 | https://shizune.co/investors/profile/guillem-laporta |
| Jan Van den Bossche | Partner | 4 | https://shizune.co/investors/profile/jan-van-den-bossche |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cyllene Therapeutics | EG 427 is a French biotechnology company that pioneers a new approach in gene therapy called pinpoint gene therapy. | $37.7M | Series C | Jul 07, 2026 |  |
| Inventiva Pharma | Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.They have built a pipeline backed by a discovery engine with an extensive library ofproprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs. | $120M | Post-IPO Equity | Jun 02, 2026 |  |
| Rivermark Medical | Rivermark Medical develops a minimally-invasive treatment for Benign Prostatic Hyperplasia (BPH) that restores urinary function. Developed by urologists to reliably reduce BPH symptoms with minimal side effects. | $20M | Series D | May 13, 2026 |  |
| exceet Card Group | exceet Card Group provides plastic, RFID, dual-interface, and chip cards for banking, government, transportation, access, and loyalty. Their competencies include design, development, consulting, production, customization, and letter shop. |  | Debt Financing | Feb 19, 2026 |  |
| Exciva | exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. | $62.2M | Series B | Jan 20, 2026 |  |
| Exciva | exciva is a Provider of targeted drug rescue program intended to involve pharmaceutical research and development based in Heidelberg, Germany. The company's program has been formulated for developing symptomatic and disease-modifying treatments, therapies, cures, prophylactics, supplements, formulations and methods of making and using suchcompositions, enabling the healthcare industry to access their program for rescuing and reusing approved drugs for new indications and new uses. | $62.2M | Series B | Jan 20, 2026 |  |
| Alveus Therapeutics | Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases. | $197M | Series A | Jan 08, 2026 |  |
| Spiro Medical | Spiro Medical is a medical device company developing a groundbreaking Pulmonary Neuromodulation (PNM) System for asthma treatment. The company offers a drug-free approach to controlling severe, chronic airway diseases through its Spiro Neuromodulation System. | $67M | Series A | Jan 07, 2026 |  |
| TargED Biopharmaceuticals | TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis. | $25.3M | Series A | Dec 16, 2025 |  |
| Artios Pharma | Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a uniquepartnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK. | $115M | Series D | Nov 17, 2025 |  |

10 of 185 investments shown.

## Co-investors
- [EQT Life Sciences](https://shizune.co/investors/profile/life-sciences-partners) — VC Fund, 20 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 18 deals together
- [Sofinnova Partners](https://shizune.co/investors/profile/sofinnova-partners) — VC Fund, 15 deals together
- [Gimv](https://shizune.co/investors/profile/gimv) — VC Fund, 14 deals together
- [Kurma Partners](https://shizune.co/investors/profile/kurma-life-science-partners) — VC Fund, 11 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 11 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [PMV](https://shizune.co/investors/profile/pmv-eu) — VC Fund
- [Limburgse Reconversie Maatschappij](https://shizune.co/investors/profile/limburgse-reconversie-maatschappij) — VC Fund
- [Qbic Fund](https://shizune.co/investors/profile/qbic-fund) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in Germany](https://shizune.co/investors/health-care-vc-funds-germany)
- [Health Care Investors in Germany](https://shizune.co/investors/health-care-investors-germany)
- [Biotechnology Investors in France](https://shizune.co/investors/biotechnology-investors-france)
- [Biotechnology VC Funds in France](https://shizune.co/investors/biotechnology-vc-funds-france)
- [Biotech Investors in France](https://shizune.co/investors/biotech-investors-france)
- [Biotech VC Funds in France](https://shizune.co/investors/biotech-vc-funds-france)

## FAQ

### What does Andera Partners invest in?

Andera Partners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Private Equity stage. Most of the 185 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Andera Partners's check size?

Andera Partners typically joins rounds of $7M–$83M at Series A, $14M–$85M at Series B and $110M–$237M at Private Equity. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Andera Partners participates in.

### How do I contact Andera Partners?

Public channels for Andera Partners include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Andera Partners?

The team at Andera Partners includes François Boudreault (Censor), Francois Xavier Mauron (Partner) and Gilles Nobecourt (Partner), among 25 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co